192 related articles for article (PubMed ID: 32168265)
41. 18F-FDG PET/CT imaging features of patients with multicentric Castleman disease.
Jiang Y; Hou G; Zhu Z; Huo L; Li F; Cheng W
Nucl Med Commun; 2021 Jul; 42(7):833-838. PubMed ID: 33741858
[TBL] [Abstract][Full Text] [Related]
42. Elevated tumor-to-liver uptake ratio (TLR) from
Huang J; Huang L; Zhou J; Duan Y; Zhang Z; Wang X; Huang P; Tan S; Hu P; Wang J; Huang M
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1958-1968. PubMed ID: 28812134
[TBL] [Abstract][Full Text] [Related]
43. 18F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine-Rituximab.
Lamonica D; Graf DA; Munteanu MC; Czuczman MS
J Nucl Med; 2017 Jan; 58(1):62-68. PubMed ID: 27469362
[TBL] [Abstract][Full Text] [Related]
44. PET-CT for Evaluation of Spleen and Liver 18F-FDG Diffuse Uptake Without Lymph Node Enlargement in Lymphoma.
Rao L; Wang X; Zong Z; Chen Z; Shi X; Yi C; Zhang X; Yang Z
Medicine (Baltimore); 2016 May; 95(20):e3750. PubMed ID: 27196500
[TBL] [Abstract][Full Text] [Related]
45. Accuracy of F-18 FDG PET/CT with optimal cut-offs of maximum standardized uptake value according to size for diagnosis of regional lymph node metastasis in patients with rectal cancer.
Bae SU; Won KS; Song BI; Jeong WK; Baek SK; Kim HW
Cancer Imaging; 2018 Sep; 18(1):32. PubMed ID: 30217167
[TBL] [Abstract][Full Text] [Related]
46. Performance of baseline FDG-PET/CT radiomics for prediction of bone marrow minimal residual disease status in the LyMa-101 trial.
Bodet-Milin C; Morvant C; Carlier T; Frecon G; Tournilhac O; Safar V; Kraeber-Bodere F; Le Gouill S; Macintyre E; Bailly C
Sci Rep; 2023 Oct; 13(1):18177. PubMed ID: 37875524
[TBL] [Abstract][Full Text] [Related]
47. FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome.
Karam M; Ata A; Irish K; Feustel PJ; Mottaghy FM; Stroobants SG; Verhoef GE; Chundru S; Douglas-Nikitin V; Oliver Wong CY; Brepoels LM
Nucl Med Commun; 2009 Oct; 30(10):770-8. PubMed ID: 19657307
[TBL] [Abstract][Full Text] [Related]
48. Prognostic Significance of FDG Uptake of Bone Marrow on PET/CT in Patients With Non-Small-Cell Lung Cancer After Curative Surgical Resection.
Lee JW; Na JO; Kang DY; Lee SY; Lee SM
Clin Lung Cancer; 2017 Mar; 18(2):198-206. PubMed ID: 27495385
[TBL] [Abstract][Full Text] [Related]
49. Relevance of monitoring metabolic reduction in patients with relapsed or refractory follicular and mantle cell lymphoma receiving bendamustine: a multicenter study.
Tateishi U; Tatsumi M; Terauchi T; Ishizawa K; Ogura M; Tobinai K
Cancer Sci; 2011 Feb; 102(2):414-8. PubMed ID: 21156007
[TBL] [Abstract][Full Text] [Related]
50. ¹⁸F-FDG PET/CT imaging for a gastrointestinal mantle cell lymphoma with multiple lymphomatous polyposis.
Saito M; Miyazaki M; Tanino M; Tanaka S; Miyashita K; Izumiyama K; Mori A; Irie T; Tanaka M; Morioka M; Tsukamoto E
World J Gastroenterol; 2014 May; 20(17):5141-6. PubMed ID: 24803832
[TBL] [Abstract][Full Text] [Related]
51. The role of 18F-FDG PET/CT in staging and restaging primary bone lymphoma.
Liu Y
Nucl Med Commun; 2017 Apr; 38(4):319-324. PubMed ID: 28225435
[TBL] [Abstract][Full Text] [Related]
52. 18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience.
Albano D; Bertoli M; Ferro P; Fallanca F; Gianolli L; Picchio M; Giubbini R; Bertagna F
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):589-597. PubMed ID: 27619357
[TBL] [Abstract][Full Text] [Related]
53. Use of 18F-FDG PET/CT imaging for evaluation of patients with primary splenic lymphoma.
Karunanithi S; Sharma P; Roy SG; Vettiyil B; Sharma A; Thulkar S; Bal C; Kumar R
Clin Nucl Med; 2014 Sep; 39(9):772-6. PubMed ID: 25036015
[TBL] [Abstract][Full Text] [Related]
54. 18F-FDG PET/CT in patients with adult-onset Still's disease.
Dong MJ; Wang CQ; Zhao K; Wang GL; Sun ML; Liu ZF; Xu L
Clin Rheumatol; 2015 Dec; 34(12):2047-56. PubMed ID: 25711875
[TBL] [Abstract][Full Text] [Related]
55. Assessment of the prognostic capacity of pretreatment, interim, and post-therapy (18)F-FDG PET/CT in extranodal natural killer/T-cell lymphoma, nasal type.
Jiang C; Zhang X; Jiang M; Zou L; Su M; Kosik RO; Tian R
Ann Nucl Med; 2015 Jun; 29(5):442-51. PubMed ID: 25801633
[TBL] [Abstract][Full Text] [Related]
56. The diagnostic ability of
Lee JW; Kim EY; Kim DJ; Lee JH; Kang WJ; Lee JD; Yun M
Eur Radiol; 2016 Dec; 26(12):4515-4523. PubMed ID: 26943133
[TBL] [Abstract][Full Text] [Related]
57. Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in mantle cell lymphoma?
Kedmi M; Avivi I; Ribakovsky E; Benyamini N; Davidson T; Goshen E; Tadmor T; Nagler A; Avigdor A
Leuk Lymphoma; 2014 Nov; 55(11):2484-9. PubMed ID: 24432895
[TBL] [Abstract][Full Text] [Related]
58. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF
Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687
[TBL] [Abstract][Full Text] [Related]
59. Increased Prostate Cancer Glucose Metabolism Detected by
Lavallée E; Bergeron M; Buteau FA; Blouin AC; Duchesnay N; Dujardin T; Tiguert R; Lacombe L; Fradet V; Makao-Nguile M; Fradet Y; Beauregard JM; Pouliot F
Eur Urol Focus; 2019 Nov; 5(6):998-1006. PubMed ID: 29609897
[TBL] [Abstract][Full Text] [Related]
60. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K
Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
